

# Carney Complex

Subjects: Genetics & Heredity

Contributor: Catherine Yang

Carney complex is a disorder characterized by an increased risk of several types of tumors. Affected individuals also usually have changes in skin coloring (pigmentation). Signs and symptoms of this condition commonly begin in the teens or early adulthood.

Keywords: genetic conditions

---

## 1. Introduction

Individuals with Carney complex are at increased risk of developing noncancerous (benign) tumors called myxomas in the heart (cardiac myxoma) and other parts of the body. Cardiac myxomas may be found in any of the four chambers of the heart and can develop in more than one chamber. These tumors can block the flow of blood through the heart, causing serious complications or sudden death. Myxomas may also develop on the skin and in internal organs. Skin myxomas appear as small bumps on the surface of the skin or as lumps underneath the skin. In Carney complex, myxomas have a tendency to recur after they are removed.

Individuals with Carney complex also develop tumors in hormone-producing (endocrine) glands, such as the adrenal glands located on top of each kidney. People with this condition may develop a specific type of adrenal disease called primary pigmented nodular adrenocortical disease (PPNAD). PPNAD causes the adrenal glands to produce an excess of the hormone cortisol. High levels of cortisol (hypercortisolism) can lead to the development of Cushing syndrome. This syndrome causes weight gain in the face and upper body, slowed growth in children, fragile skin, fatigue, and other health problems.

People with Carney complex may also develop tumors of other endocrine tissues, including the thyroid, testes, and ovaries. A tumor called an adenoma may form in the pituitary gland, which is located at the base of the brain. A pituitary adenoma usually results in the production of too much growth hormone. Excess growth hormone leads to acromegaly, a condition characterized by large hands and feet, arthritis, and "coarse" facial features.

Some people with Carney complex develop a rare tumor called psammomatous melanotic schwannoma. This tumor occurs in specialized cells called Schwann cells, which wrap around and insulate nerves. This tumor is usually benign, but in some cases it can become cancerous (malignant).

Almost all people with Carney complex have areas of unusual skin pigmentation. Brown skin spots called lentiginos may appear anywhere on the body but tend to occur around the lips, eyes, or genitalia. In addition, some affected individuals have at least one blue-black mole called a blue nevus.

## 2. Frequency

Carney complex is a rare disorder; fewer than 750 affected individuals have been identified.

## 3. Causes

Mutations in the *PRKAR1A* gene cause most cases of Carney complex. This gene provides instructions for making one part (subunit) of an enzyme called protein kinase A, which promotes cell growth and division (proliferation). The subunit produced from the *PRKAR1A* gene, called type 1 alpha, helps control whether protein kinase A is turned on or off.

Most mutations in the *PRKAR1A* gene that cause Carney complex result in an abnormal type 1 alpha subunit that is quickly broken down (degraded) by the cell. The lack of this subunit causes protein kinase A to be turned on more often than normal, which leads to uncontrolled cell proliferation. The signs and symptoms of Carney complex are related to the unregulated growth of cells in many parts of the body.

Some individuals with Carney complex do not have identified mutations in the *PRKAR1A* gene. In many of these cases, the disorder is associated with a specific region on the short (p) arm of chromosome 2, designated as 2p16. Researchers have not discovered the gene within this region that is responsible for Carney complex.

### 3.1. The Gene Associated with Carney Complex

- *PRKAR1A*

## 4. Inheritance

Carney complex is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In approximately 80 percent of cases, an affected person inherits the mutation from one affected parent. The remaining cases result from new mutations in the gene and occur in people with no history of Carney complex in their family.

## 5. Other Names for This Condition

- Carney Syndrome
- LAMB - Lentiginos, atrial myxoma, mucocutaneous myoma, blue nevus syndrome
- NAME - Nevi, atrial myxoma, skin myxoma, ephelides syndrome

---

## References

1. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libe R, René-Corail F, Stergiopoulos S, Bourdeau I, Bei T, Clauser E, Calender A, Kirschner LS, Bertagna X, Carney JA, Stratakis CA. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (*PRKAR1A*): phenotype analysis in 353 patients and 80 different genotypes. *J Clin Endocrinol Metab.* 2009 Jun;94(6):2085-91. doi: 10.1210/jc.2008-2333.
2. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. *Medicine (Baltimore).* 1985 Jul;64(4):270-83.
3. Horvath A, Bertherat J, Groussin L, Guillaud-Bataille M, Tsang K, Cazabat L, Libe R, Remmers E, René-Corail F, Faucz FR, Clauser E, Calender A, Bertagna X, Carney JA, Stratakis CA. Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (*PRKAR1A*): an update. *Hum Mutat.* 2010 Apr;31(4):369-79. doi: 10.1002/humu.21178.
4. Horvath A, Bossis I, Giatzakis C, Levine E, Weinberg F, Meoli E, Robinson-White A, Siegel J, Soni P, Groussin L, Matyakhina L, Verma S, Remmers E, Nesterova M, Carney JA, Bertherat J, Stratakis CA. Large deletions of the *PRKAR1A* gene in Carney complex. *Clin Cancer Res.* 2008 Jan 15;14(2):388-95. doi:10.1158/1078-0432.CCR-07-1155.
5. Horvath A, Stratakis CA. Carney complex and lentiginosis. *Pigment Cell Melanoma Res.* 2009 Oct;22(5):580-7. doi: 10.1111/j.1755-148X.2009.00613.x.
6. Kirschner LS. Use of mouse models to understand the molecular basis of tissue-specific tumorigenesis in the Carney complex. *J Intern Med.* 2009 Jul;266(1):60-8. doi: 10.1111/j.1365-2796.2009.02114.x. Review.
7. Mateus C, Palangí A, Franck N, Groussin L, Bertagna X, Avril MF, Bertherat J, Dupin N. Heterogeneity of skin manifestations in patients with Carney complex. *J Am Acad Dermatol.* 2008 Nov;59(5):801-10. doi: 10.1016/j.jaad.2008.07.032.
8. Stratakis CA, Raygada M. Carney Complex. 2003 Feb 5 [updated 2018 Aug 16]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from <http://www.ncbi.nlm.nih.gov/books/NBK1286/>